Chapter 1.Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2.Executive Summary
Chapter 3.Global CD Targeted Cell Therapy Market Snapshot
Chapter 4.Global CD Targeted Cell Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5.Market Segmentation 1: By Indication Type Estimates & Trend Analysis
5.1. By Indication Type & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Indication Type:
5.2.1. Diffuse large B-cell lymphoma
5.2.2. Chronic lymphocytic leukemia
5.2.3. Multiple myeloma
5.2.4. Acute lymphoblastic leukemia
5.2.5. Others
Chapter 6.Market Segmentation 2: By Target Type Estimates & Trend Analysis
6.1. By Target Type & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Target Type:
6.2.1. CD19
6.2.2. CD20
6.2.3. CD33
Chapter 7.CD Targeted Cell Therapy Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Indication Type, 2023-2031
7.1.2. North America CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Type, 2023-2031
7.1.3. North America CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe CD Targeted Cell Therapy Market revenue (US$ Million) by By Indication Type, 2023-2031
7.2.2. Europe CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Type, 2023-2031
7.2.3. Europe CD Targeted Cell Therapy Market revenue (US$ Million) by country, 2023-2031
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific CD Targeted Cell Therapy Market revenue (US$ Million) by By Indication Type, 2023-2031
7.3.2. Asia Pacific CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Type, 2023-2031
7.3.3. Asia Pacific CD Targeted Cell Therapy Market revenue (US$ Million) by country, 2023-2031
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America CD Targeted Cell Therapy Market revenue (US$ Million) by By Indication Type, 2023-2031
7.4.2. Latin America CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Type, 2023-2031
7.4.3. Latin America CD Targeted Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2023-2031
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. Middle East & Africa
7.5.1. Middle East & Africa CD Targeted Cell Therapy Market revenue (US$ Million) by By Indication Type, (US$ Million)
7.5.2. Middle East & Africa CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Type, 2023-2031
7.5.3. Middle East & Africa CD Targeted Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2023-2031
7.5.3.1. South Africa
7.5.3.2. GCC Countries
7.5.3.3. Rest of MEA
Chapter 8.Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Juno Therapeutics
8.2.2. Agios Pharmaceutical
8.2.3. Aurora BioPharma
8.2.4. Atara Biotherapeutics
8.2.5. AryoGen Biopharma
8.2.6. Shenzhen BinDeBio Ltd.
8.2.7. China Immunotech Co., Ltd.
8.2.8. Autolus Limited
8.2.9. Kite Pharma
8.2.10. Bellicum Pharmaceuticals
8.2.11. bluebird bio
8.2.12. Calibr
8.2.13. Carina Biotech
8.2.14. CARsgen Therapeutics
8.2.15. Celgene Corporation
8.2.16. Cellectis
8.2.17. Cell Medica
8.2.18. AbbVie
8.2.19. Allogene Therapeutics
8.2.20. Amgen
8.2.21. Cell Design Labs
8.2.22. Celularity
8.2.23. Celyad
8.2.24. Fate Therapeutics
8.2.25. Fortress Bio
8.2.26. Gilead Sciences
8.2.27. Sorrento Therapeutics, Inc.
8.2.28. Ziopharm
8.2.29. Janssen Biotech
8.2.30. JW Therapeutics
8.2.31. Medisix Therapeutics
8.2.32. Mustang Bio
8.2.33. Nanjing Legend Biotech
8.2.34. Precision Biosciences
8.2.35. Posedia Therapeutics
8.2.36. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.